Date: 2017-06-15
Type of information: Collaboration agreement
Compound:
Company: TiGenix (Belgium) Crohn's and Colitis Foundation's President's Corporate Circle (USA - NY) European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) (Belgium)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Type agreement: collaboration
Action mechanism:
Disease: Crohn's disease, ulcerative colitis
Details:
- • On June 15, 2017, TiGenix announced partnerships with the largest patient advocacy groups focused on Crohn's disease and ulcerative colitis. In the United States, TiGenix has joined the Crohn's and Colitis Foundation's President's Corporate Circle, and in Europe, TiGenix has signed a sponsorship agreement with the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA). The company will work with both organizations to broaden the understanding and awareness of complex perianal fistulas in Crohn's disease.
- TiGenix is currently developing Cx601 for the treatment of complex perianal fistulas. The Company has filed Cx601 for potential approval in Europe with the European Medicines Agency (EMA) and anticipates a decision in the second half of 2017. In addition, on 13th June, TiGenix announced the launch of a global pivotal Phase III study to support a future regulatory filing in the U.S.
Financial terms:
Latest news:
Is general: Yes
